Brian Feagan

1.1k total citations
34 papers, 404 citations indexed

About

Brian Feagan is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Brian Feagan has authored 34 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Genetics, 20 papers in Epidemiology and 7 papers in Surgery. Recurrent topics in Brian Feagan's work include Inflammatory Bowel Disease (31 papers), Microscopic Colitis (19 papers) and Eosinophilic Esophagitis (5 papers). Brian Feagan is often cited by papers focused on Inflammatory Bowel Disease (31 papers), Microscopic Colitis (19 papers) and Eosinophilic Esophagitis (5 papers). Brian Feagan collaborates with scholars based in United States, Canada and Belgium. Brian Feagan's co-authors include William J. Sandborn, Stefan Schreiber, Stephen B. Hanauer, Jean‐Frédéric Colombel, Richard N. Fedorak, Lloyd Mayer, Séverine Vermeire, Simon Travis, Michael A. Kamm and Paul Rutgeerts and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and Clinical Pharmacokinetics.

In The Last Decade

Brian Feagan

29 papers receiving 392 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Feagan United States	8	314	248	105	76	40	34	404
D. J. Buurman Netherlands	7	244 0.8×	157 0.6×	154 1.5×	50 0.7×	24 0.6×	8	338
Arnold Stronkhorst Netherlands	9	157 0.5×	91 0.4×	77 0.7×	100 1.3×	30 0.8×	22	310
Josh Korzenik United States	5	179 0.6×	112 0.5×	60 0.6×	79 1.0×	21 0.5×	7	325
C. Bascietto Italy	7	283 0.9×	201 0.8×	96 0.9×	98 1.3×	55 1.4×	11	359
A. G. Press Germany	9	190 0.6×	129 0.5×	38 0.4×	82 1.1×	24 0.6×	11	323
Claire Liefferinckx Belgium	8	181 0.6×	136 0.5×	83 0.8×	55 0.7×	14 0.3×	23	230
H Malchow Germany	7	259 0.8×	158 0.6×	107 1.0×	121 1.6×	20 0.5×	32	405
Dahham Alsoud Belgium	9	239 0.8×	137 0.6×	73 0.7×	69 0.9×	8 0.2×	21	292
Matthew C. Choy Australia	8	231 0.7×	168 0.7×	69 0.7×	77 1.0×	11 0.3×	22	312
Carmen S. Horjus Talabur Horje Netherlands	11	211 0.7×	129 0.5×	153 1.5×	95 1.3×	18 0.5×	18	346

Countries citing papers authored by Brian Feagan

Since Specialization

Citations

This map shows the geographic impact of Brian Feagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Feagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Feagan more than expected).

Fields of papers citing papers by Brian Feagan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Feagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Feagan. The network helps show where Brian Feagan may publish in the future.

Co-authorship network of co-authors of Brian Feagan

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Feagan. A scholar is included among the top collaborators of Brian Feagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Feagan. Brian Feagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allegretti, Jessica R., Andrés Yarur, Brian Feagan, et al.. (2025). TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH RO7790121 DEMONSTRATES EARLY CLINICAL RESPONSE AND SYMPTOM IMPROVEMENT – RESULTS FROM THE PHASE 2B TUSCANY-2 TRIAL. Gastroenterology. 168(3). S17–S18.

Vermeire, Séverine, Marla Dubinsky, Brian Feagan, et al.. (2024). P113 Maintenance of week 12 response through week 52 with etrasimod in patients with ulcerative colitis in ELEVATE UC 52. Poster presentations. A119.1–A119.

Danese, Silvio, Michael E. Rothenberg, Jeremy J. Lim, et al.. (2024). A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 23(8). 1387–1397. 1 indexed citations

Sands, Bruce E., et al.. (2018). Ustekinumab Improves Productivity and Reduces Work Limitation of Patients With Moderate to Severe Crohnʼs Disease: Results From Three Phase 3 Clinical Trials. The American Journal of Gastroenterology. 113(Supplement). S352–S352. 1 indexed citations

Reinisch, Walter, Geert D’Haens, Gert De Hertogh, et al.. (2018). P046 HISTOLOGIC MEASURES OF MUCOSAL HEALING CORRELATE WITH ENDOSCOPIC MEASURES OF DISEASE ACTIVITY AT BASELINE AND FOLLOWING INDUCTION THERAPY WITH THE JANUS KINASE 1 INHIBITOR FILGOTINIB IN ACTIVE CROHN’S DISEASE: RESULTS FROM FITZROY STUDY. Gastroenterology. 154(1). S24–S24. 4 indexed citations

Peyrin‐Biroulet, Laurent, David T. Rubin, Brian Feagan, et al.. (2018). 20 ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT. Gastroenterology. 154(1). S17–S18. 4 indexed citations

Casteele, Niels Vande, Diane R. Mould, Jason Coarse, et al.. (2017). Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease. Clinical Pharmacokinetics. 56(12). 1513–1523. 29 indexed citations

Sandborn, William J., C Gasink, Daphne Chan, et al.. (2016). Endoscopic Healing in Induction and Maintenance with Ustekinumab in the Phase 3 UNITI Crohnʼs Disease Program: 2016 ACG Presidential Poster Award. The American Journal of Gastroenterology. 111. S278–S279. 2 indexed citations

Feagan, Brian, Corey A. Siegel, Gil Melmed, et al.. (2015). Efficacy of Vedolizumab Maintenance Therapy With and Without Continued Immunosuppressant Use in GEMINI 1 and GEMINI 2. The American Journal of Gastroenterology. 110. S791–S791. 2 indexed citations

10.

Sandborn, William J., Jean–Frédéric Colombel, Brian Feagan, et al.. (2013). Early and Sustained Remission after Treatment with Subcutaneously Administered Golimumab Is Associated with Normalized Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Post-hoc Analysis from PURSUIT Induction and Maintenance Trials. The American Journal of Gastroenterology. 108. S519–S519. 2 indexed citations

11.

Sandborn, William J., Brian Feagan, Colleen Marano, et al.. (2012). Clinical Response Is a Meaningful Endpoint in Ulcerative Colitis Clinical Studies. Inflammatory Bowel Diseases. 18. S26–S27. 3 indexed citations

12.

Sandborn, William J., Brian Feagan, Scott Lee, et al.. (2011). Baseline C-reactive Protein (CRP) and Plasma Anti-TNF Concentration in Patients with Active Crohnʼs Disease Treated with certolizumab pegol (CZP). The American Journal of Gastroenterology. 106. S454–S454. 1 indexed citations

13.

Rutgeerts, Paul, Walter Reinisch, Diederik Esser, et al.. (2011). A post-hoc analysis. Inflammatory Bowel Diseases. 17(suppl_1). S6–S6. 6 indexed citations

14.

Panaccione, Remo, Glenn L. Gordon, Scott Lee, et al.. (2010). Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohnʼs Disease (CD). The American Journal of Gastroenterology. 105. S457–S458. 5 indexed citations

15.

Paterson, William G., J. Springer, Michael O’Mahony, et al.. (2008). 377 A Randomized, Double-Blind, Placebo-Controlled Trial with a Novel Dual Noradrenergic Reuptake Inhibitor (NARI) and 5-HT3 Antagonist: Results of a Phase II 8-Week Study in Female Patients with Diarrhea Predominant Irritable Bowel Syndrome (D-IBS). Gastroenterology. 134(4). A–50. 4 indexed citations

16.

Sandborn, William J., Gary R. Lichtenstein, Stefan Schreiber, & Brian Feagan. (2008). The Long-Term, 30 Months, Efficacy and Tolerability of Certolizumab Pegol Therapy for Crohnʼs Disease. The American Journal of Gastroenterology. 103. S429–S429. 4 indexed citations

17.

Clark, Mike, Jean‐Frédéric Colombel, Brian Feagan, et al.. (2007). American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology. 133(1). 312–339. 177 indexed citations

18.

Hommes, Daniël W., Filip Baert, Gert Van Assche, et al.. (2005). Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down Therapy. Gastroenterology. 129(1). 371–371. 42 indexed citations

19.

Schreiber, Stefan, Massimo Campieri, Jean‐Frédéric Colombel, et al.. (2001). Use of anti-tumour necrosis factor agents in inflammatory bowel disease. International Journal of Colorectal Disease. 16(1). 1–11. 36 indexed citations

20.

Hanauer, Stephen B., Gary R. Lichtenstein, Lloyd Mayer, et al.. (2001). Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the accent i trial. Gastroenterology. 120(5). A21–A21. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact